Material and Methods
RAPPORT is a multi-institutional, single arm, phase 1b/II clinical trial (NCT02855203). Patients with 1-5 oligometastases from clear cell RCC were eligible. They received a single fraction SABR of 18-20Gy to all metastases (or 30Gy in 10 fractions of conventional radiotherapy if SABR was not feasible) followed by 8 x 3 weekly cycles of 200mg intravenous pembrolizumab. This is a preplanned interim safety analysis of the first 12 patients who completed SABR and 12 weeks of pembrolizumab. Adverse events were graded using CTCAE v4.0. Results At the date of reporting 25 patients with 76 metastases have been enrolled. The mean age is 62 years, with 18 males and 7 females enrolled. The commonest site of metastasis is lung (n=38, 50%). Most patients have ECOG performance status 0 (64%), with a minority ECOG 1 (36%). For the pre-specified interim safety analysis, 12 patients with a total 37 metastases were irradiated, with 32 (86%) receiving SABR and 5 (14%) receiving conventional radiotherapy. The number of lesions per patient was 1 in 3 patients (25%), 3 in 4 patients (33%), 4 in 3 patients (25%) and 5 in 2 patients (17%). The predominant site of metastases was the lung (n=24, 65%). No treatment courses were abandoned due toxicity (radiotherapy + 8 cycles of pembrolizumab), although one patient ceased treatment early due to progressive disease. Grade 1 and graded 2 treatment related adverse events were recorded in 6 patients (50%, mixed events) and 1 patient (hypothyroidism, 8%), respectively. No grade 3 or greater treatment related adverse events were recorded.
Conclusion
The combination of SABR + pembrolizumab in a small cohort of patients to date is well tolerated. Based on this interim safety analysis the independent safety monitoring committee have recommended continuation of planned recruitment (n=30 
